APSR2026-209

 
Late-Breaking
Withdrawn
Withdrawn
 
 
 
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1206907-46904-APSR 2026 - Chylothorax Poster PDF_434029.pdf
Format: PDF Only
01. Clinical Respiratory Medicine
2

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Zen Sara Tan * Auburn Hospital General Medicine Auburn Australia Auburn Hospital General Medicine Auburn Australia
Johnny Siu - Auburn Hospital General Medicine Auburn Australia St George Hospital Respiratory and Sleep Medicine Kogarah Australia
 
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Zen Sara
Tan
zensaratzy@gmail.com
+61423159623
31-40
Australia
Case Report
Chylothorax revealing metastatic ovarian carcinoma
Maximum 25 words
Abstract Content
 
 
 
 
Chylothorax is a recognised but uncommon complication of malignancy. Lymphoma accounts for the majority of malignant cases, while solid organ tumours are infrequently implicated. We report a case of metastatic ovarian carcinoma presenting with chylothorax.
A 79-year-old woman presented with a two-month history of progressive dyspnoea, pleuritic chest pain and fatigue. CT demonstrated a large left-sided pleural effusion (Figure 1) with associated para-aortic lymphadenopathy, and thoracentesis yielded milky white fluid. Pleural fluid analysis demonstrated an exudative effusion with a markedly elevated triglyceride level of 9.6 mmol/L (>1.24 mmol/L diagnostic threshold) and a low cholesterol level of 3.0 mmol/L (<5.18 mmol/L), consistent with chylothorax (Bhatnagar M et al, Journal of Thoracic Disease, 2024, 16, 834-846). PET demonstrated marked FDG avidity initially raising concern for lymphoma, however biopsy of a para-aortic node subsequently confirmed metastatic high-grade serous carcinoma consistent with ovarian origin. Following initial drainage, the effusion recurred with symptomatic deterioration. Definitive pleural management options, including indwelling pleural catheter placement and surgical pleurodesis, were considered. Given her preserved functional status and the need for timely systemic therapy, pleural drainage was performed as a temporising measure while expediting chemotherapy, with longer-term pleural intervention guided by treatment response.
Solid organ malignancies are a relatively uncommon cause of chylothorax. This case emphasises the potential for diagnostic anchoring when FDG-avid nodal disease accompanying chylothorax is presumed to be lymphoma. Given the non-specific nature of PET avidity, histological confirmation is crucial, as management differs significantly between lymphoma and metastatic solid tumours, including breast, lung, gastrointestinal and gynaecological primaries. In solid malignancy, chylothorax most commonly results from secondary lymphatic obstruction due to nodal metastases rather than direct thoracic duct invasion. Initial management consists of drainage and conservative measures including dietary modification and adjunctive therapy such as somatostatin analogues. Long-term resolution is largely determined by effective systemic therapy directed at the underlying tumour, with interventional approaches reserved for refractory or persistent effusions. Awareness of this uncommon presentation supports timely biopsy and appropriate oncological referral in patients presenting with chylothorax and nodal disease.
 
 
Yes
Yes
https://storage.unitedwebnetwork.com/files/1285/1206907-37089-Figure1ChylothoraxCT_373168.png
JPG or JPEG or PNG format ONLY
Chylothorax, Pleural effusion, Lymphatic disorder
maximum 3 keywords and no abbreviations, separated by commas
The authors declare no conflicts of interest and no external funding was received for this work.
341